Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Soler

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 28, 2023
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthmaAnju T Peters, Hironori Sagara, Jonathan Corren, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 15, 2023
Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE studyMichael Blaiss, Eugene R Bleecker, Juby Jacob-Nara, et al.
The Journal of Allergy and Clinical Immunology|August 26, 2024
Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE studyEugene Bleecker, Michael Blaiss, Juby Jacob-Nara, et al.
Annals of the American Thoracic Society|February 1, 2024
Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 AsthmaAlberto Papi, Mario Castro, William W Busse, et al.
Chest|December 4, 2024
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPDBartolome R Celli, Antonio Anzueto, Dave Singh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2022
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polypsPatrick Berger, Andrew Menzies-Gow, Anju T Peters, et al.
Journal of Asthma and Allergy|June 11, 2024
Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global RegistryNijra L Lugogo, Enrico Heffler, Vicente Plaza, et al.
Chest|December 4, 2024
Stability of Fractional Exhaled Nitric Oxide and Its Relationship With Exacerbation in Patients Aged 6 Years or Older With Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Ian D Pavord, Michael E Wechsler, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 12, 2022
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthmaLawrence D Sher, Giovanni Passalacqua, Camille Taillé, et al.
Respiratory Medicine|September 2, 2023
Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthmaJorge F Maspero, Shirin Shafazand, Jeremy Cole, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 28, 2023
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthmaAnju T Peters, Hironori Sagara, Jonathan Corren, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 15, 2023
Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE studyMichael Blaiss, Eugene R Bleecker, Juby Jacob-Nara, et al.
The Journal of Allergy and Clinical Immunology|August 26, 2024
Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE studyEugene Bleecker, Michael Blaiss, Juby Jacob-Nara, et al.
Annals of the American Thoracic Society|February 1, 2024
Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 AsthmaAlberto Papi, Mario Castro, William W Busse, et al.
Chest|December 4, 2024
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPDBartolome R Celli, Antonio Anzueto, Dave Singh, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 10, 2022
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polypsPatrick Berger, Andrew Menzies-Gow, Anju T Peters, et al.
Journal of Asthma and Allergy|June 11, 2024
Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global RegistryNijra L Lugogo, Enrico Heffler, Vicente Plaza, et al.
Chest|December 4, 2024
Stability of Fractional Exhaled Nitric Oxide and Its Relationship With Exacerbation in Patients Aged 6 Years or Older With Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Ian D Pavord, Michael E Wechsler, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 12, 2022
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthmaLawrence D Sher, Giovanni Passalacqua, Camille Taillé, et al.
Respiratory Medicine|September 2, 2023
Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthmaJorge F Maspero, Shirin Shafazand, Jeremy Cole, et al.
Pageof 8